top of page

The CEO of Syntis Bio describes a novel obesity program that entered the clinic today and a broader platform that leverages the small intestine to impact metabolism and drug absorption

  • blonca9
  • Jun 11, 2024
  • 1 min read

Rahul Dhanda describes the technology that Syntis uses to coat the upper region of the small intestine to modulate nutrient uptake, and the benefits this confers on metabolism and drug development.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTVHQ

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Genezen_Logo_RGB.png

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page